Shinobi Therapeutics

Shinobi Therapeutics is a company specializing in iPS cell therapies that are designed to evade the immune system. They aim to revolutionize cancer treatment and address other debilitating diseases by developing therapies that work with, rather than against, the body's natural defenses. Their proprietary immune evasion technology shields iPS-derived cells from immune rejection, enabling increased persistence, reduced lymphodepletion, redosability, and off-the-shelf availability.

Shinobi’s innovative “Katana” platform enables rapid pipeline expansion by introducing CARs or TCRs to a master cell bank of untargeted iPS-T cells. This approach is poised to significantly accelerate and reduce the cost of developing new therapies, making cell therapies more accessible to a broader patient population. Led by an esteemed team of industry leaders and pioneers, Shinobi is headquartered in South San Francisco and has strong roots in Kyoto, Japan.

Shinobi Therapeutics is a company dedicated to revolutionizing cell therapy by developing immune evasive iPSC-derived cell therapies. They aim to overcome the limitations of current cell therapies by creating treatments that work with the patient's immune system rather than against it. This approach allows for increased persistence, reduced lymphodepletion, redosability, and off-the-shelf availability, leading to better outcomes for more patients. Shinobi's focus is on treating solid tumors and other intractable diseases, including autoimmune disorders, by slashing costs, cutting timelines, and providing treatments for millions of patients.

Shinobi Therapeutics promotes a culture of innovation and collaboration, driven by a passionate team of industry leaders and pioneers. They are focused on pioneering the next frontier of cell therapy by developing immune evasive iPSC-derived cell therapies that are accessible to a wider range of patients. The company emphasizes a team-oriented approach, partnering with top-tier institutions and welcoming contributions from investors, partners, and team members. Their website highlights the dedication and expertise of their leadership team, reflecting a commitment to excellence and progress in the field of cell therapy.